Glytec Appoints Dr. Jordan Messler as Chief Medical Officer
Experienced Physician and Glycemic Expert to Drive Safe Clinical Best Practices as Company Scales to Hospitals across the Country
WALTHAM, MASS. (July 13, 2021) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the appointment of Jordan Messler, MD, SFHM, FACP to Chief Medical Officer. In this new role, Dr. Messler will be responsible for spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development while supporting the delivery, customer, quality and regulatory teams to ensure ethical and safe glycemic management best practices.
Messler joined Glytec in October 2018 as the Executive Director of Clinical Practice. Before Glytec, he was the Medical Director for the Morton Plant Hospitalist group, in Clearwater, FL, where he continues to work as a hospitalist. A highly skilled physician with deep expertise in glycemic management, Messler trained in internal medicine at Emory University in Atlanta and subsequently served as an academic hospitalist for several years after residency.
“Managing blood sugar levels for patients in the hospital is a major challenge for most health systems and it doesn’t get nearly enough attention,” said Messler. “Glytec is a leader in the movement to solve this challenge, delivering proven software with exceptional research to back it up. I’m honored to continue this mission and expand my role at our growing company.”
The new executive appointment builds upon a strong start to the year for Glytec. In April 2021, Glytec announced $21 million in funding to help set the standard for hospital insulin dosing and glycemic management. Just two months later, the company named Nausheen Moulana its Chief Technology Officer. Messler will partner with Moulana and the rest of the Glytec team to accelerate clinical research, oversee the continuation of safe product development and scale into hospitals across the United States.
“Jordan is a terrific partner and the perfect leader for this new role,” said Ed Furlong, President and Chief Executive Officer, Glytec. “He’s proven himself to be a valuable clinical asset to our team with a broad scope of knowledge and deep engagement with every department in our organization. With Jordan at the helm of our clinical practice, we’ll continue to deliver safe, effective solutions and revolutionary research that keeps our company at the cutting edge of inpatient glycemic management.”
Messler holds a bachelor’s degree in cellular and molecular biology from Duke University and a doctorate in medicine from the University of South Florida. He is also the current physician editor for the Society of Hospital Medicine’s (SHM) blog, The Hospital Leader. A veteran leader with a passion for teaching, Messler has also chaired SHM’s Quality and Patient Safety Committee and supported several national mentoring programs, including Project BOOST and Glycemic Control.
To learn more about Glytec, visit: https://glytecsystems.com.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) and LinkedIn, or visit www.GlytecSystems.com.
fama PR for Glytec
MAR-0000357 Rev 1.0